Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03593694 · ClinicalTrials.gov registry record · NA
Technology Delivered Diabetes-Modified Behavioral Activation Treatment
A NA study, sponsored by State University of New York at Buffalo.
- Terminated
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT03593694: Clinical Trial NA study, sponsored by State University of New York at Buffalo.
NCT03593694 is a NA study that was terminated before completion, run by State University of New York at Buffalo. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03593694, a NA study, was terminated before completion, sponsored by State University of New York at Buffalo.
- TERMINATED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
The overarching goal of this proposal is to test the efficacy of a multi-component, high intensity intervention, technology delivered, diabetes-modified behavioral activation treatment (TECH DM-BAT) that incorporates: 1) diabetes education; 2) home telemonitoring; and 3) diabetes modified behavioral activation, delivered by nurses via smartphones is effective in improving metabolic control in African Americans with poorly controlled type 2 diabetes.
Primary Outcome
Change from Baseline Hemoglobin A1c (HbA1c) at 3 and 6 months
Interventions
- BEHAVIORAL TECH DM-BAT
- BEHAVIORAL TECH DMBAT Active Comparator
- BEHAVIORAL TECH DMBAT Other
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-11-06 |
| Est. Completion | 2019-04-30 |
| Phase | NA |
Why NCT03593694 stopped before completion
NCT03593694 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which TECH DM-BAT is the first listed.
NCT03593694 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03593694 about?
NCT03593694 is a clinical study titled "Technology Delivered Diabetes-Modified Behavioral Activation Treatment". The overarching goal of this proposal is to test the efficacy of a multi-component, high intensity intervention, technology delivered, diabetes-modified behavioral activation treatment (TECH DM-BAT) that incorporates: 1) diabetes education; 2) home telemonitoring; and 3) diabetes modified behavioral...
What is the current status of trial NCT03593694?
This trial is currently terminated. It is a NA study. The enrollment target is 30 participants. The study started on 2017-11-06. Estimated completion is 2019-04-30.
What interventions are being tested in trial NCT03593694?
The interventions under investigation include: TECH DM-BAT (BEHAVIORAL), TECH DMBAT Active Comparator (BEHAVIORAL), TECH DMBAT Other (BEHAVIORAL).
Who is sponsoring clinical trial NCT03593694?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03593694's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI